I am a bit of a coin collector, and recently I visited my favorite coin shop in downtown Louisville.  I was met with this news: A coin dealer I know in Austin, Indiana had been killed recently, murdered in his own coin shop, shot in the head by robbers.  Four persons were later arrested when coins belonging to this elderly man were found in their possession.  Austin, Indiana is, by ...

Read more...

After a New York pharmaceutical company recently raised the price of a drug that’s been around for more than 60 years from $13 to $750 a pill, the nation appeared to collectively gasp over a seemingly capricious, “anything goes” approach to drug pricing. The move also revived a recurring debate over whether pharmaceuticals should have free rein to charge outrageously high prices for important medications. Madness? Perhaps. But pharmaceutical companies are simply responding ...

Read more...

The other day, the mother of a nine-week-old baby girl called my office in a panic.  Her daughter was having terrible breathing trouble, with coughing and wheezing.  She asked to been seen that day, and of course I said yes. I asked mom how the baby had been doing overall, and she said that she’d had some noisy breathing as a newborn, but all was well until the past few ...

Read more...

The letter from the insurance company was addressed to my patient. The two pages of information boiled down to one simple sentence: “After a thorough review, our decision to not cover the medication Provigil (modafinil) is unchanged.” The letter went on to explain that there was no further recourse, and that the medication would not be approved because it was not Food and Drug Administration–approved for the condition my patient had: ...

Read more...

Last year, there was a rash of ill-researched articles in the press claiming a connection between the HPV vaccine and POTS (postural orthostatic hypotension syndrome) and CRPS (chronic regional pain syndrome).  Toronto Star, The Independent, Daily Mail I’m looking at you. These articles read like propaganda for anti-HPV vaccine groups. They all followed such a similar format that I wondered if they had ...

Read more...

According to a study published in the New England Journal of Medicine, the use of dietary supplements sends an estimated 23,000 Americans to the emergency department each year. Approximately 25 percent of the ER visits that were supplement related were by adults who were using herbal weight loss products. Another 10 percent were caused by adults consuming “energy products” (although people using energy drinks were excluded from the ...

Read more...

An August, 2015 study in Multidisciplinary Respiratory Medicine is being touted as evidence that homeopathy is as effective as antibiotics for respiratory infections in children. It doesn’t show that at all -- in fact, it doesn’t show anything, except that crappy studies in crappy journals can nonetheless be used to manipulate opinion. Beware. First, the study itself. Researchers in Italy looked at about 90 children with ordinary ...

Read more...

A new study in JAMA Internal Medicine finds that two-thirds of cancer drugs considered by the U.S. Food and Drug Administration (FDA) over the past five years were approved without evidence that they improve health outcomes or length of life. (This study closely corroborates and acknowledges the findings published last year by John Fauber of the Milwaukee Journal Sentinel and Elbert Chu of MedPage Today.) Follow-up studies showed ...

Read more...

Most of my patients think about pain medicines in terms of the symptoms they treat. “This is my headache medicine, and this is my arthritis medicine,” they often say. Health care providers are more likely to categorize pain medicines by the way they work: some are anti-inflammatory, some affect nerve endings, and others influence how the brain perceives pain. But the truth is that no matter how you classify pain ...

Read more...

Recently, the clinically positive results from the CLEOPATRA oncology trial were released, showing that pertuzumab, when added to docetaxel and trastuzumab as first-line chemotherapy, produces an average survival benefit of 15.7 months in HER2 positive breast cancer patients. That good news notwithstanding, the authors calculated that Genentech’s price for adding pertuzumab to gain one quality adjusted life year is a breathtaking $713,219. In dry academic language, the ...

Read more...

Most Popular